General Information
Drug ID
DR00193
Drug Name
Tamoxifen
Synonyms
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Citofen; Crisafeno; Diemon; Gen-Tamoxifen; Istubal (TN); Istubol; Nolvadex (TN); Nolvadex-D; Nourytam; Novaldex; Novo-Tamoxifen; Oncomox; Pms-Tamoxifen; Retaxim; TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); TRANS FORM OF TAMOXIFEN; Tamizam; Tamone; Tamoplex (TN); Tamoxen; Tamoxifen (Hormonal therapy); Tamoxifen (INN); Tamoxifen (TN); Tamoxifen (Z); Tamoxifen [INN:BAN]; Tamoxifen and its salts; Tamoxifene; Tamoxifene [INN-French]; Tamoxifeno [INN-Spanish]; Tamoxifeno;Tamoxifenum; Tamoxifenum [INN-Latin]; Tomaxithen; Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; Trans-Tamoxifen; Valodex; Valodex (TN)
Drug Type
Small molecular drug
Indication Breast cancer [ICD11: 2C60-2C6Z] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=2733526"></iframe>
3D MOL 2D MOL
Formula
C26H29NO
Canonical SMILES
CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3
InChI
InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-
InChIKey
NKANXQFJJICGDU-QPLCGJKRSA-N
CAS Number
CAS 10540-29-1
Pharmaceutical Properties Molecular Weight 371.524 Topological Polar Surface Area 12.5
Heavy Atom Count 28 Rotatable Bond Count 8
Hydrogen Bond Donor Count 0 Hydrogen Bond Acceptor Count 2
PubChem CID
2733526
PubChem SID
11113844 , 14853108 , 24900307 , 26697206 , 26752017 , 26752018 , 30091348 , 4266414 , 46393636 , 46487938 , 46505515 , 47213210 , 47216564 , 47364953 , 47364954 , 47364955 , 47588786 , 47662047 , 47662048 , 47662049 , 47736233 , 47959503 , 48184778 , 48258990 , 48334237 , 48427434 , 49688681 , 49698369 , 49854602 , 50104683 , 50104684 , 50104685 , 50104686 , 53789476 , 56310641 , 56310662 , 56310717 , 56310801 , 56311275 , 56311294 , 56311693 , 56311998 , 56312239 , 56312443 , 56312444 , 603542 , 7886804 , 7980727 , 8794645 , 9319
ChEBI ID
ChEBI:41774
TTD Drug ID
D07KSG
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
MRP7 Transporter Info Multidrug resistance-associated protein 7 Substrate [3]
P-GP Transporter Info P-glycoprotein 1 Substrate [4]
Drug-Transporter Activity Data
Drug-Transporter Activity Data MRP7 Transporter Info Km = 0.078 microM LLC-PK1 cells-MRP7 [3]
References
1 Tamoxifen was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
3 Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
4 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.